3-Hydroxyphthalic anhydride (3-HPA) is a valuable building block in organic synthesis. It is typically synthesized through the oxidation of 3-hydroxytoluene with potassium permanganate or chromic acid. 3-HPA is known for its ability to undergo various reactions, including esterification, amidation, and condensation, leading to the formation of diverse compounds with potential applications in pharmaceuticals, polymers, and dyes. Its presence as a key intermediate in the synthesis of various bioactive molecules, such as anti-inflammatory agents and anticancer drugs, has spurred extensive research efforts focused on its synthesis and functionalization. The compound's ability to form stable chelates with metal ions makes it a promising candidate for metal-organic frameworks (MOFs) and coordination polymers, which are emerging materials for applications in gas storage, catalysis, and separation. Further exploration of 3-HPA's chemistry holds the potential to unlock its full potential in various fields.'
3-hydroxyphthalic anhydride: used to modify proteins [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 96580 |
| CHEMBL ID | 2057864 |
| SCHEMBL ID | 382951 |
| MeSH ID | M0455060 |
| Synonym |
|---|
| 4-hydroxyisobenzofuran-1,3-dione |
| 4-hydroxy-isobenzofuran-1,3-dione |
| 3-hydroxyphthalic anhydride treated whey |
| 3-hydroxyphthalic anhydride treated egg albumin grade iv |
| 3-hydroxyphthalic anhydride treated purified ovomucoid |
| 3-hydroxyphthalic anhydride treated partially purified ovomucoid |
| 3-hydroxyphthalic anhydride treated .beta.-lactoglobulin from bovine whey |
| 1,3-isobenzofurandione, 4-hydroxy- |
| 3-hydroxyphthalic anhydride treated bsa |
| 3-hydroxyphthalic anhydride treated egg white |
| 3-hydroxyphthalic anhydride treated casein |
| 37418-88-5 |
| nsc80858 |
| nsc-80858 |
| 3-hydroxyphthalic anhydride |
| nsc 80858 |
| 3-hydroxyphthalic acid anhydride |
| brn 0135783 |
| phthalic anhydride, 3-hydroxy- |
| 3-hydroxyphthalic anhydride, 98% |
| 4-hydroxy-2-benzofuran-1,3-dione |
| F2147-1038 |
| A6397 |
| 4-hydroxy-1,3-dihydro-2-benzofuran-1,3-dione |
| unii-rt7fsx9ybd |
| rt7fsx9ybd , |
| 5-18-03-00184 (beilstein handbook reference) |
| CHEMBL2057864 |
| STK930474 |
| AKOS005660534 |
| BP-13154 |
| FT-0639372 |
| hydroxyphthalic anhydride |
| CCTOEAMRIIXGDJ-UHFFFAOYSA-N |
| SCHEMBL382951 |
| AC-29923 |
| DTXSID10190860 |
| CS-W005592 |
| mfcd00011557 |
| 3-hydroxy-phthalic acid anhydride |
| BCP15658 |
| SY039506 |
| AS-10283 |
| AMY19150 |
| BBL036792 |
| P15398 |
| 4-hydroxy-1,3-isobenzofurandione |
| SB40546 |
| EN300-75262 |
| 3-hydroxy-phthalicanhydrid |
| HY-W005592 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " After the vaginal application of JB01 in 38 women for 3 months, no serious adverse events were reported, and normalization of the vaginal micro-environment has been observed." | ( Safety evaluation of chemically modified beta-lactoglobulin administered intravaginally. Guo, X; Jiang, S; Lu, L; Meng, Y; Qiu, L; Wang, Y; Zhu, Y, 2016) | 0.43 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID673436 | Binding affinity to GST-tagged PPARgamma LBD at 50 uM after 4 hrs by TR-FRET competitive binding assay | 2012 | Bioorganic & medicinal chemistry, Aug-15, Volume: 20, Issue:16 | Design and synthesis of marine fungal phthalide derivatives as PPAR-γ agonists. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.22) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (10.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||